Oxytocin and neonatal hyperbilirubinemia: A prospective cohort study by Abbas, Shakib Shafi et al.
Abbas et al. Oxytocin and neonatal jaundice
Vol 2 | Issue 3 | Jul - Sep 2015 Indian J Child Health 129
Short Communication
Oxytocin and neonatal hyperbilirubinemia: A prospective cohort study
Shakib Shafi Abbas, Jemila James, N Sreedevi, P M C Nair
From Department of Pediatrics & Neonatology, Sree Gokulam Medical College and Research Foundation, Thiruvananthapuram, 
Kerala, India
Correspondence to: Dr. Shakib Shafi Abbas, Mundol House, Paramba, Thekkil PO, Kasaragod - 671 541, Kerala, India.
Phone: +91-9447714189, E-mail: drshakibshafi@gmail.com
Received – 07 April 2015 Initial Review – 25 May 2015 Published Online – 06 August 2015
Abstract
Objective: To study the incidence of neonatal jaundice requiring phototherapy in babies exposed to maternal oxytocin for induction 
of labor and to compare the increase in neonatal jaundice in oxytocin group with the jaundice in babies born of spontaneous labor. 
Materials and Methods: This prospective cohort study was conducted in the neonatal unit of a tertiary care center in Trivandrum, 
Kerala over a period of 6 months. After exclusion, 308 babies were divided in two groups, Group A (babies exposed to maternal 
oxytocin for induction of labor) or Group B (babies born of spontaneous labor with oxytocin use for augmentation of labor). Babies were 
observed daily for clinical jaundice till discharge. Results: Incidence of neonatal jaundice in Group A was 52% and in Group B was 12% 
with relative risk 4.3 (95% confidence interval: 2.69-6.73). Conclusion: Our study shows that maternal oxytocin used for induction 
of labor increase the incidence of neonatal jaundice, and it is logical to prevent hyperbilirubinemia by reducing the dose of oxytocin.
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Hyperbilirubinemia is often a benign condition of the neonates which can affect about 60% of the term and 80% of the preterm infants [1]. One of the possible 
reasons for increased incidence of neonatal hyperbilirubinemia 
(NNH) in healthy term babies is the widespread use of oxytocic 
drugs in the management of labor. This association between 
maternal oxytocin use and NNH is well-documented in 
studies [2]. Fetal erythrocytes are less deformable after oxytocin-
induced labor than after spontaneous labor. In-vitro studies 
showed a time related and dose related reduction in erythrocyte 
deformability in response to oxytocin administration [1].
We have observed that the use of phototherapy in healthy 
term babies without risk factors (ABO or Rh incompatibility, 
cephalhematoma, low birth weight [LBW], and sepsis, etc.) for 
neonatal jaundice has been increased in our unit. Since oxytocin 
is often administered intravenously to induce or accelerate labor, 
we have felt that it is mandatory to make a critical appraisal of the 
association between maternal oxytocin use and the incidence of 
NNH in our unit. We have planned this study with the objective 
of estimation of the incidence of NNH requiring phototherapy 
in babies exposed to maternal oxytocin for induction of labor 
and comparison of incidences of NNH in the babies exposed to 
maternal oxytocin and in babies born of spontaneous labor.
MATERIALS AND METHODS
This prospective cohort study was conducted in the neonatal 
unit of a tertiary care hospital where facilities for newborn 
intensive care is available. The study was conducted over 
a period of 6 months (01-02-2014 to 31-07-2014) after 
obtaining clearance from the Institutional Ethical Committee. 
Informed written consent was obtained from the parents of 
the eligible neonates before recruitment. Our study did not 
affect obstetricians’ decision in giving oxytocin. All healthy 
term (≥37 weeks) normal birth weight babies born during the 
study period were eligible for inclusion in the study. Babies 
with ABO and Rh blood group settings, cephalhematoma, 
LBW (LBW i.e., birth weight <2500 g) babies, who required 
extensive resuscitation, suspected/probable sepsis, and babies 
whose siblings required exchange transfusion for NNH were 
excluded from the study.
Recruited babies were grouped in two groups, either 
Group A (babies exposed to maternal oxytocin for induction 
of labor) or Group B (babies born of spontaneous labor with 
oxytocin use for augmentation of labor only). The dose of 
oxytocin used for induction of labor was 5-10 IU, whereas 
dose for augmentation of labor was <5 IU. Babies from both 
groups were observed daily for clinical jaundice till discharge. 
Blood for serum bilirubin was obtained from a peripheral vein, 
in babies with clinical jaundice. Serum bilirubin was estimated 
by automated total bilirubin method (using diazotized sulfanilic 
acid). Phototherapy was started on those babies whose serum 
bilirubin was above the photo zone, as in the nomogram 
clinical management of jaundice [3]. Observer assured that 
breast feeding was established in those babies who received 
phototherapy.
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The data were entered prospectively into a Microsoft Excel 
sheet and the results were analyzed using SPSS statistics 
version 20. The incidence of neonatal jaundice in each group 
was analyzed independently, and their relative risk (RR) and 
95% confidence interval (CI) were calculated. The statistical 
test used for analysis was Chi-square test/Fisher’s exact test. 
p values reported are 2 tailed, and a p≤0.05 is considered 
statistically significant.
RESULTS
Of the 402 healthy term babies born during the study period, 
308 babies were enrolled in the study after excluding 
94 babies (27 and 14 babies with ABO and Rh incompatibility 
respectively, 24 LBW babies, 16 babies with suspected or 
probable sepsis, 7 babies with cephalhematoma, and 6 sick 
babies). Of 308 babies, 161 were exposed to maternal oxytocin 
(Group A) and 147 babies were born of spontaneous labor 
(Group B). There were 81 males and 80 females in Group A 
while in Group B, there were 82 males and 65 females. The 
mean birth weight in Group A was 3150±446 g and in Group B 
was 2950±386 g. Mean gestational age in Group A was 
38.0±1.23 weeks and in Group B was 38.20±2.56 weeks.
Mean maternal oxytocin dose in Group A and Group B 
was 8.24±2.66 IU and 3.18±1.34 IU, respectively. In Group A, 
84 babies and 18 babies in Group B developed jaundice 
requiring phototherapy. None of the babies required exchange 
transfusion during the study period. Mean peak bilirubin level 
on post natal day 3 in Group A was 19.1±3.56 mg% and in 
Group B was 12.4±2.68 mg/dl. The incidence of neonatal 
jaundice in Group A and in Group B was 0.52 and 0.12, 
respectively, with RR of 4.3 (95% CI: 2.69-6.73), showing a 
significant association (p<0.0001).
DISCUSSION
Bilirubin toxicity remains a significant problem despite recent 
advances in the care of neonates with jaundice. Kernicterus, 
though infrequent, is the cause of 10% of the mortalities and 
at least 70% of the long-term morbidities in these neonates [4]. 
Oxytocin crossing the placenta affected deformability was 
shown in the in-vitro studies, with the finding of both a time-
related and dose-related effect of oxytocin on erythrocyte 
deformability in the range of oxytocin concentrations 
found in maternal blood during induction of labor with 
oxytocin [3]. These in-vitro results also help to explain the 
clinical observations that the NNH after induction of labor is 
related to the dose and the duration of oxytocin administration. 
Our study also supported this increase in erythrocyte destruction 
during oxytocin-induced labor.
The vasopressin-like action of oxytocin causes activation of 
electrolyte and water transport across the erythrocyte membrane 
with consequent osmotic swelling, which is a well-recognized 
cause of reduced erythrocyte deformability and leads to more 
rapid erythrocyte destruction. In the neonate, whose hepatic 
enzymes are unable to cope with the increased bilirubin 
production, clinical hyperbilirubinemia ensues. Oxytocin is 
an important therapeutic agent in obstetrics and probably its 
use cannot be stopped and thus its effect on erythrocytes also 
cannot be prevented. However, it would be logical to prevent 
the hyperbilirubinemia by reducing the dose of oxytocin.
CONCLUSION
Our study implies that maternal oxytocin used for induction of 
labor is responsible for the higher bilirubin values. It is logical 
to prevent hyperbilirubinemia by reducing the dose of oxytocin, 
as oxytocin has shown a dose-related response in developing 
neonatal jaundice.
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